Recently, Mondello et al. reported that HDAC3 inhibitor was able to restore the MHC class II expression in CREBBP-deficient tumor cells, and HDAC3 inhibition represented a novel immune-epigenetic therapy for CREBBP mutant lymphomas [73]. The gene discussed is CREBBP; the disease is neoplasm.